Skip to main content

Elena Vargas Accarino

Institutions of which they are part

Postdoctoral researcher
Liver Diseases
Vall Hebron Institut de Recerca

Elena Vargas Accarino

Institutions of which they are part

Postdoctoral researcher
Liver Diseases
Vall Hebron Institut de Recerca

Projects

Malalties hepàtiques

IP: Joan Genescà Ferrer
Collaborators: Beatriz Minguez Rosique, Sergi Colomer Castell, Elena Vargas Accarino, Immaculada Raurell Saborit, Lluís Viladomiu Catà, Lluis Castells Fusté, Maria del Mar Riveiro Barciela, Malalties hepàtiques, Maria Buti Ferret, Montserrat Gomez Perez, Malalties hepàtiques, Judit Vico Romero, Josep Quer Sivila, Adriana Palom Agusti, Juan Manuel Pericàs Pulido, Maria Nieves Martell Pérez-Alcalde, Damir Garcia Cehic, Daniel Martinez Vazquez, Laura Puente Ramo, Isabel Campos Varela, María Bermúdez Ramos, Juan Ignacio Esteban Mur, Ester Palacio Gutierrez, Susana Anton Calvo, Monica Higuera Urbano, Meritxell Ventura Cots, Ares Aurora Villagrasa Vilella, Emma Bigas Alsina, Carolina Campos Martinez, Macarena Simon-Talero Horga, Malalties hepàtiques, David Tabernero Caellas, Mònica Pons Delgado, Marcella Salzano, Malalties hepàtiques
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 60000
Reference: 2021 SGR 00462
Duration: 01/01/2022 - 30/06/2025

Aislamiento y caracterización molecular de Células Tumorales Circulantes (CTCs): potenciales biomarcadores en Carcinoma Hepatocelular

IP: Beatriz Minguez Rosique
Collaborators: Itxarone Izaskun Bilbao Aguirre, Elena Vargas Accarino, Maria Teresa Salcedo Allende, Monica Higuera Urbano
Funding agency: Instituto de Salud Carlos III
Funding: 183920
Reference: PI21/00714
Duration: 01/01/2022 - 31/12/2024

Desarrollo de un test rápido de diagnóstico precoz de hepatocarcinoma en biopsia líquida, usando PCR en tiempo real y secuenciación masiva.

IP: Maria Buti Ferret
Collaborators: Elena Vargas Accarino, Laia Perez Lasarte
Funding agency: Instituto de Salud Carlos III
Funding: 82400
Reference: FI18/00027
Duration: 01/01/2019 - 13/04/2023

Related news

Using computed tomography (CT), with or without contrast, it is possible to perform an accurate and safe detection of the disease without the need for biopsies and avoiding the limitations of other non-invasive diagnostic tools.

Preliminary study results confirm that the drug resmetirom reduces the presence of fat, inflammation, cell damage and fibrosis in the liver.

The European project, in which Vall d'Hebron participates, will favor personalized diagnosis and innovative therapeutic strategies in patients with the disease.

Related professionals

Anna Llort Sales

Anna Llort Sales

Childhood Cancer and Blood Disorders
Read more
Marc Simo Perdigo

Marc Simo Perdigo

Molecular Medical Imaging
Read more
Joaquim Sola  Santesmases

Joaquim Sola Santesmases

Zelador/a
General Services and Infrastructures Unit
Manager
Read more
Javier Domeño Baztán

Javier Domeño Baztán

Research technician
Clinical Neuroimmunology
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.